This site is intended for healthcare professionals
News

FDA accepts for priority review applications for Opdivo in combination with Cabometyx in advanced renal cell carcinoma. -BMS + Exelixis.

Read time: 1 mins
Last updated:28th Jun 2021
Published:20th Oct 2020
Condition: Renal Cell Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest